CGTLive Staff

Review top news and interview highlights from the week ending August 5, 2022.

Review top news and interview highlights from the week ending July 29, 2022.

Review top news and interview highlights from the week ending July 22, 2022.

Review top news and interview highlights from the week ending July 15, 2022.

Review top news and interview highlights from the week ending July 1, 2022.

Review top news and interview highlights from the week ending June 24, 2022.

Review top news and interview highlights from the week ending June 17, 2022.

Review top news and interview highlights from the week ending June 10, 2022.

Review top news and interview highlights from the week ending May 27, 2022.

Review top news and interview highlights from the week ending May 20, 2022.

Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.

Review top news and interview highlights from the week ending May 13, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.

Tim Lu, MD, PhD, CEO and co-founder of gene circuit company Senti Bio, joins CGTL to discuss his company's approach to creating "smarter" therapies, including its CAR-NK platform.

Marker Therapeutics is taking a multi-antigen approach to developing next-generation T-cell therapies.

Review top news and interview highlights from the week ending May 6, 2022.

Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending April 29, 2022.

The CEO and managing director of Chimeric Therapeutics hopes to contribute to the narrative with a handful of offerings in development across 2 platforms: CORE-NK, which uses allogeneic natural killer cells, and T-cell derived autologous therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Lexeo recently announced FDA clearance of its investigational new drug application for LX2006 for Friedreich's ataxia cardiomyopathy.

Review top news and interview highlights from the week ending April 15, 2022.

Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.

Ruhong Jiang, PhD, cofounder, president, and chief executive officer of ASC Therapeutics, joins CGTL to discuss the company's AAV8-based gene therapy for patients with hemophilia A, as well as other pipeline activity.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Matt Killeen, PhD, chief scientific officer at Renovacor, shares updates on the company's lead candidate, REN-001, an adeno-associated viral vector serotype 9-based gene therapy for the treatment of BAG3-associated dilated cardiomyopathy.

Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, joins CGTL to discuss ImmTOR, an immune tolerance platform that could ultimately enable gene therapy redosing in certain cases.

David Apelian, MD, PhD, MBA, chief executive officer at BlueSphere Bio; and Warren Shlomchik, MD, cofounder and scientific advisory board chairman at BlueSphere Bio, join CGTL to discuss the company's leading T-cell therapy clinical program.